120 related articles for article (PubMed ID: 38661028)
1. TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL-1.
Cai Y; Li Y; Xu Y; Yang W; Huang M
FASEB J; 2024 Apr; 38(8):e23625. PubMed ID: 38661028
[TBL] [Abstract][Full Text] [Related]
2. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
Bradley A; Zheng H; Ziebarth A; Sakati W; Branham-O'Connor M; Blumer JB; Liu Y; Kistner-Griffin E; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Landen CN; Eblen ST
Carcinogenesis; 2014 May; 35(5):1100-9. PubMed ID: 24379240
[TBL] [Abstract][Full Text] [Related]
3. Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells.
Park SH; Lee DH; Kim JL; Kim BR; Na YJ; Jo MJ; Jeong YA; Lee SY; Lee SI; Lee YY; Oh SC
Oncotarget; 2016 Sep; 7(37):59503-59518. PubMed ID: 27517746
[TBL] [Abstract][Full Text] [Related]
4. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.
Matsuura K; Huang NJ; Cocce K; Zhang L; Kornbluth S
Oncogene; 2017 Mar; 36(12):1698-1706. PubMed ID: 27721409
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA LINC00152 promotes cell proliferation through competitively binding endogenous miR-125b with MCL-1 by regulating mitochondrial apoptosis pathways in ovarian cancer.
Chen P; Fang X; Xia B; Zhao Y; Li Q; Wu X
Cancer Med; 2018 Sep; 7(9):4530-4541. PubMed ID: 30030896
[TBL] [Abstract][Full Text] [Related]
7. Tobramycin suppresses HUWE1 degradation to control MCL-1 stability during tumour development.
He J; Wu S; Li X; Tang L; Chen H; Qin L; Xie J; Lu T; Xu W
Clin Exp Pharmacol Physiol; 2020 Sep; 47(9):1600-1610. PubMed ID: 32378766
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells.
Tong J; Wang P; Tan S; Chen D; Nikolovska-Coleska Z; Zou F; Yu J; Zhang L
Cancer Res; 2017 May; 77(9):2512-2521. PubMed ID: 28202514
[TBL] [Abstract][Full Text] [Related]
9. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
Ye M; Zhang Y; Zhang X; Zhang J; Jing P; Cao L; Li N; Li X; Yao L; Zhang J; Zhang J
Cancer Res; 2017 Jul; 77(13):3527-3539. PubMed ID: 28522751
[TBL] [Abstract][Full Text] [Related]
10. Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.
Bonnefond ML; Lambert B; Giffard F; Abeilard E; Brotin E; Louis MH; Gueye MS; Gauduchon P; Poulain L; N'Diaye M
Apoptosis; 2015 Apr; 20(4):535-50. PubMed ID: 25627260
[TBL] [Abstract][Full Text] [Related]
11. Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells.
Pervin S; Tran A; Tran L; Urman R; Braga M; Chaudhuri G; Singh R
Br J Cancer; 2011 Jul; 105(3):428-37. PubMed ID: 21730980
[TBL] [Abstract][Full Text] [Related]
12. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
13. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
14. BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer.
Habata S; Iwasaki M; Sugio A; Suzuki M; Tamate M; Satohisa S; Tanaka R; Saito T
Int J Oncol; 2016 Jul; 49(1):402-10. PubMed ID: 27120977
[TBL] [Abstract][Full Text] [Related]
15. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
Tong J; Tan S; Zou F; Yu J; Zhang L
Oncogene; 2017 Feb; 36(6):787-796. PubMed ID: 27399335
[TBL] [Abstract][Full Text] [Related]
16. KRIBB11 accelerates Mcl-1 degradation through an HSF1-independent, Mule-dependent pathway in A549 non-small cell lung cancer cells.
Kang MJ; Yun HH; Lee JH
Biochem Biophys Res Commun; 2017 Oct; 492(3):304-309. PubMed ID: 28859986
[TBL] [Abstract][Full Text] [Related]
17. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
[TBL] [Abstract][Full Text] [Related]
18. CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination.
Zhu Y; Liang L; Zhao Y; Li J; Zeng J; Yuan Y; Li N; Wu L
J Nanobiotechnology; 2024 Jan; 22(1):35. PubMed ID: 38243224
[TBL] [Abstract][Full Text] [Related]
19. CRL4B
Liu F; Cao L; Zhang T; Chang F; Xu Y; Li Q; Deng J; Li L; Shao G
Biochem Biophys Res Commun; 2018 Jun; 501(2):440-447. PubMed ID: 29738775
[TBL] [Abstract][Full Text] [Related]
20. Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons.
Magiera MM; Mora S; Mojsa B; Robbins I; Lassot I; Desagher S
Cell Death Differ; 2013 Feb; 20(2):281-92. PubMed ID: 22976837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
